Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 219

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Open access
· 2017 · New England Journal of Medicine

Abstract

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisTo the Editor: The conclusions of Simpson and colleagues (Dec.15 issue) 1 regarding the effectiveness and quality-of-life-enhancing capacity of dupilumab in patients with atopic dermatitis open new perspectives in the strategies of treatment of allergic diseases, because interleukin-4 and interleukin-13 are "type 2 inflammatory cytokines that may be important drivers of atopic or allergic diseases."Given the good results in patients with asthma 2 or nasal polyposis, 3 we as pediatricians look with interest to the possibilities arising from these studies involving adults.However, the higher rate of allergic conjunctivitis in the dupilumab-treated population than in the placebo group in this trial runs against these wishes.Although we agree with the authors that "further studies on the causes of conjunctivitis are warranted," could these be cases of atopic keratoconjunctivitis rather than simple allergic conjunctivitis?This condition is often linked to atopic dermatitis.4 If so, could it be hypothesized that the blockage of interleukin-4 and interleukin-13 increases the activity of the specific ligands involved in atopic keratoconjunctivitis (e.g., the OX40 ligand) in the eye, an immunologically privileged area? 5 This would limit the potential uses of dupilumab in the allergy field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1700366

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 219

Metadata

Venue
New England Journal of Medicine
Published
2017-03-16
Volume
376
Issue
11
Pages
1090-1091
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4237210808
Cited by
219
References
3
FWCI
26.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. https://app.cochat.ai/papers/10.1056/nejmc1700366
The paper
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. (2017). New England Journal of Medicine. https://doi.org/10.1056/nejmc1700366

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.